Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | SDHB | P21912 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL14655585 | 0.97 | CYP1A2 (0.41) | CYP1A2CYP3A4LOXL2ASIC3HCRTR1 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655584 | 0.87 | LOXL2 (0.40) | CYP1A2CYP3A4LOXL2ASIC3PTPN1 | |
| SCHEMBL10271516 | 0.83 | ASIC3 (0.53) | LOXL2ASIC3HCRTR1HCRTR2TP53 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655599 | 0.82 | CYP2A6 (0.51) | CYP1A2CYP3A4ASIC3PTPN1MEN1 | |
| Hydrochloric Acid SCHEMBL28148503 | 0.81 | ASIC3 (0.52) | LOXL2ASIC3HCRTR1HCRTR2TP53 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655667 | 0.80 | NPC1 (0.51) | CYP3A4TP53RAB9A | |
| Trifluoromethanesulfonic Acid SCHEMBL29770051 | 0.80 | NPC1 (0.51) | CYP3A4TP53RAB9A | |
| Trifluoromethanesulfonic Acid SCHEMBL14655598 | 0.80 | CYP2A6 (0.51) | CYP1A2CYP3A4ASIC3PTPN1MEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655602 | 0.79 | MAPKAPK2 (0.41) | CYP1A2CYP3A4ASIC3PTPN1MEN1 | |
| Dimethyl Sulfoxide SCHEMBL10806279 | 0.79 | ASIC3 (0.46) | CYP1A2CYP3A4LOXL2ASIC3HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220302396-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2022-09-22 | — | — | US | disclosed |
| US-11380854-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2022-07-05 | — | — | US | disclosed |
| US-20190245153-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2019-08-08 | — | — | US | disclosed |
| US-10312458-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20160099425-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION | 2016-04-07 | — | — | US | disclosed |
| US-9184397-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2551933-B1 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORP (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140159028-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2014-06-12 | — | — | US | disclosed |
| US-8709615-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130026452-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2551933-A1 | Heteroleptic iridium complexes as dopants | Universal Display Corporation (US) | 2013-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-20160099425-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-20140159028-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-20190245153-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-10312458-B2 | Organic electroluminescent materials and devices | JUND, OCIAD1, OCIAD2 | CYP1A2 1748/4885CYP3A4 581/4885LOXL2 2240/4885 |
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-20130026452-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-11380854-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
| US-20220302396-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP1A2 2375/4885CYP3A4 1215/4885LOXL2 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.